| |
|
|
|
|
|
 |
| |
|
±×¸®°Õ¿¬Áúݼ¿ GREEGEN SOFT CAP.[µ¿¹°´ãºÐ¸» , Ergocalciferol , Vitamin A oil]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Aµî±Þ
(ergocalciferol;vitamin a; )
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Vitamin A¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Ergocalciferol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Vitamin D2 is the form of vitamin D most commonly added to foods and nutritional supplements. Vitamin D2 must be transformed (hydroxylated) into one of two active forms via the liver or kidney. Once transformed, it binds to the vitamin D receptor that then leads to a variety of regulatory roles. Vitamin D plays an important role in maintaining calcium balance and in the regulation of parathyroid hormone (PTH). It promotes renal reabsorption of calcium, increases intestinal absorption of calcium and phosphorus, and increases calcium and phosphorus mobilization from bone to plasma. Vitamin D2 and its analogs appear to promote intestinal absorption of calcium through binding to a specific receptor in the mucosal cytoplasm of the intestine. Subsequently, calcium is absorbed through formation of a calcium-binding protein.
|
| Pharmacology |
Ergocalciferol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Used in the treatment of hypcalcemia and in dialysis-dependent renal failure. Ergoalcifediol (Vitamin D2) is a fat soluble steroid hormone precursor of vitamin D that contributes to the maintenance of normal levels of calcium and phosphorus in the bloodstream.
|
| Metabolism |
Ergocalciferol¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Cytochrome P450 24A1 (CYP24A1)
|
| Protein Binding |
Ergocalciferol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ >99.8%
|
| Half-life |
Ergocalciferol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 19 to 48 hours (however, stored in fat deposits in body for prolonged periods).
|
| Absorption |
Ergocalciferol¿¡ ´ëÇÑ Absorption Á¤º¸ Readily absorbed from small intestine (proximal or distal), requires presence of bile salts.
|
| Pharmacokinetics |
ErgocalciferolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : Àå±â Åõ¿©½Ã : ¾à 1°³¿ù
- Èí¼ö :
- À§Àå°üÀ¸·ÎºÎÅÍ Àß Èí¼öµÈ´Ù.
- Èí¼ö¿¡´Â ´ãÁóÀÌ ÇÊ¿äÇÏ´Ù.
- °£ Áúȯ, ´ã°ü Áúȯ, À§Àå°ü Áúȯ¿¡¼´Â Èí¼ö°¡ °¨¼ÒÇÒ ¼ö ÀÖ´Ù.
- ºÐÆ÷ : Èí¼ö ÈÄ chylomicronsÀ» ÅëÇØ Ç÷ÁßÀ¸·Î ¼ö¼ÛµÇ¸ç, ÁÖ·Î °£¿¡ ÀúÀåµÇ°í ±âŸ Áö¹æ, ±ÙÀ°, ÇǺΠ¹× °ñ Á¶Á÷ µî¿¡µµ Á¸ÀçÇÑ´Ù.
- ´Ü¹é°áÇÕ : ÁÖ·Î vitamin D-binding ¥á-globulin¿¡ °áÇÕÇϸç albumin°úµµ °áÇÕÇÑ´Ù.
- ´ë»ç : °£ ¹× ½ÅÀå¿¡¼ Ȱ¼ºÇüÀÎ calcitriol·Î ´ë»çµÈ´Ù.
- ¹Ý°¨±â : 25-[OH] D : 16ÀÏ
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 4-8 ½Ã°£ À̳»
- ¼Ò½Ç : ÁÖ·Î ´ãÁó ¹× ´ëº¯À» ÅëÇØ ¹è¼³µÇ¸ç ¼Ò·®Àº ´¢¸¦ ÅëÇØ ¹è¼³µÈ´Ù.
Vitamin A oilÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- Èí¼ö :
- RetinolÀº ¼ÒÀå¿¡¼ Èí¼öµÇ¸ç retinoic acid´Â ¹®¸ÆÀ» ÅëÇØ Àü½ÅÀûÀ¸·Î Èí¼öµÈ´Ù.
- »ý¸®Àû º¸Ãæ·®ÀÇ ¿ë·® ÀÌÇÏ¿¡¼´Â Àß Èí¼öµÈ´Ù.
- À¯È Á¦Á¦º¸´Ù ¼ö¿ë¼º Á¦Á¦°¡ º¸´Ù ½Å¼ÓÇÏ°Ô Èí¼öµÈ´Ù.
- °í¿ë·®, ÁöÁú Èí¼öÀå¾Ö, Àú´Ü¹é½ÄÀÌ, °£Áúȯ, ÃéÀå Áúȯ¿¡¼´Â Èí¼ö°¡ ÀúÇϵȴÙ.
- ¸²ÇÁÀÇ chylomicrons¿¡ ÀÇÇØ °£À¸·Î ¼ö¼ÛµÈ´Ù.
- ºÐÆ÷ :
- °£¿¡ °í³óµµ·Î ÀúÀåµÈ´Ù. (¾à 2³â µ¿¾ÈÀÇ ¿ä±¸·®ÀÌ °£¿¡ ÀúÀåµÊ)
- À¯Áó ºÐºñ
- RBP (retinol-binding protein)¿¡ °áÇÕµÈ retinolÀÇ ÇüÅ·Π°£À¸·ÎºÎÅÍ ¿î¹ÝµÈ´Ù.
- ´ë»ç : glucuronide Æ÷ÇÕ, Àå°£¼øÈ¯
- ¼Ò½Ç : ´ãÁóÀ» ÅëÇØ ´ëº¯À¸·Î ¹è¼³µÈ´Ù.
|
| Biotransformation |
Ergocalciferol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Within the liver, ergocalciferol is hydroxylated to ercalcidiol (25-hydroxyergocalciferol) by the enzyme 25-hydroxylase. Within the kidney, ercalcidiol serves as a substrate for 1-alpha-hydroxylase, yielding ercalcitriol (1,25-dihydroxyergocalciferol), the biologically active form of vitamin D2.
|
| Toxicity |
Ergocalciferol¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50 = 23.7 mg/kg (Orally in mice); LD50 = 10 mg/kg (Orally in rats ); Nausea, vomiting and diarrhea, weight loss, irritability, weakness, fatigue, lassitude, and headache.
|
| Drug Interactions |
Ergocalciferol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Ergocalciferol¿¡ ´ëÇÑ Description Á¤º¸ Ergocalciferol (Vitamin D2) is a derivative of ergosterol formed by ultraviolet rays breaking of the C9-C10 bond. It differs from cholecalciferol in having a double bond between C22 and C23 and a methyl group at C24. [PubChem]
|
| Dosage Form |
Ergocalciferol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Capsule Oral
|
| Drug Category |
Ergocalciferol¿¡ ´ëÇÑ Drug_Category Á¤º¸ Antihypocalcemic AgentsAntihypoparathyroid AgentsBone Density Conservation AgentsEssential VitaminVitaminsVitamins (Vitamin D)
|
| Smiles String Canonical |
Ergocalciferol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC(C)C(C)C=CC(C)C1CCC2C1(C)CCCC2=CC=C1CC(O)CCC1=C
|
| Smiles String Isomeric |
Ergocalciferol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC(C)[C@@H](C)\C=C\[C@@H](C)[C@H]1CC[C@@H]2[C@]1(C)CCC\C2=C/C=C1/C[C@@H](O)CCC1=C
|
| InChI Identifier |
Ergocalciferol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C28H44O/c1-19(2)20(3)9-10-22(5)26-15-16-27-23(8-7-17-28(26,27)6)12-13-24-18-25(29)14-11-21(24)4/h9-10,12-13,19-20,22,25-27,29H,4,7-8,11,14-18H2,1-3,5-6H3/b10-9+,23-12+,24-13-/t20-,22+,25-,26+,27-,28+/m0/s1
|
| Chemical IUPAC Name |
Ergocalciferol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol
|
| Drug-Induced Toxicity Related Proteins |
VITAMIN A ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Retinol-binding protein, cellular Drug:vitamin a Toxicity:acute inflammation . [¹Ù·Î°¡±â] Replated Protein:Retinol-binding protein (RBP) Drug:vitamin a Toxicity:renal osteodystrophy. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-06-24
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|